

Peter J Halfmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3184381/publications.pdf>

Version: 2024-02-01

76
papers

10,805
citations

109321
35
h-index

76900
74
g-index

94
all docs

94
docs citations

94
times ranked

14467
citing authors

#	ARTICLE	IF	CITATIONS
1	Mediator complex subunit 12 is a gatekeeper of SARS-CoV-2 infection in breast cancer cells. <i>Genes and Diseases</i> , 2022, 9, 5-8.	3.4	2
2	Ambient Temperature Stable, Scalable COVID-19 Polymer Particle Vaccines Induce Protective Immunity. <i>Advanced Healthcare Materials</i> , 2022, 11, e2102089.	7.6	14
3	Durability of immune responses to the BNT162b2 mRNA vaccine. <i>Med</i> , 2022, 3, 25-27.	4.4	33
4	SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. <i>Nature</i> , 2022, 603, 687-692.	27.8	475
5	Long-term, infection-acquired immunity against the SARS-CoV-2 Delta variant in a hamster model. <i>Cell Reports</i> , 2022, 38, 110394.	6.4	9
6	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	30.7	577
7	Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model. <i>MBio</i> , 2022, 13, e0304421.	4.1	17
8	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. <i>Nature</i> , 2022, 602, 664-670.	27.8	917
9	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	27.8	117
10	Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters. <i>Cell Reports</i> , 2022, 39, 110688.	6.4	14
11	A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. <i>Viruses</i> , 2022, 14, 562.	3.3	2
12	SARS-CoV-2 Interference of Influenza Virus Replication in Syrian Hamsters. <i>Journal of Infectious Diseases</i> , 2022, 225, 282-286.	4.0	25
13	mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2. <i>Med</i> , 2022, 3, 309-324.e6.	4.4	6
14	Nasally delivered interferon- β protects mice against infection by SARS-CoV-2 variants including Omicron. <i>Cell Reports</i> , 2022, 39, 110799.	6.4	39
15	Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. <i>Science Translational Medicine</i> , 2022, 14, eabm4908.	12.4	21
16	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. <i>Nature</i> , 2022, 607, 119-127.	27.8	174
17	Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. <i>Nature Communications</i> , 2022, 13, .	12.8	93
18	Novel modulators of p53-signaling encoded by unknown genes of emerging viruses. <i>PLoS Pathogens</i> , 2021, 17, e1009033.	4.7	12

#	ARTICLE	IF	CITATIONS
19	SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike. MBio, 2021, 12, .	4.1	81
20	Protective Immunity and Persistent Lung Sequelae in Domestic Cats after SARS-CoV-2 Infection. Emerging Infectious Diseases, 2021, 27, 660-663.	4.3	23
21	Transmission of SARS-CoV-2 in domestic cats imposes a narrow bottleneck. PLoS Pathogens, 2021, 17, e1009373.	4.7	84
22	A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus. Immunity, 2021, 54, 815-828.e5.	14.3	34
23	Hypergraph models of biological networks to identify genes critical to pathogenic viral response. BMC Bioinformatics, 2021, 22, 287.	2.6	39
24	Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Communications Biology, 2021, 4, 597.	4.4	35
25	Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity, 2021, 54, 1290-1303.e7.	14.3	101
26	The landscape of antibody binding in SARS-CoV-2 infection. PLoS Biology, 2021, 19, e3001265.	5.6	58
27	Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2. ImmunoHorizons, 2021, 5, 466-476.	1.8	23
28	Characterization of a new SARS-CoV-2 variant that emerged in Brazil. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	63
29	Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds. Bioengineering and Translational Medicine, 2021, 6, e10253.	7.1	19
30	Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. MBio, 2021, 12, e0198721.	4.1	57
31	Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition. Journal of Virology, 2021, 95, e0136821.	3.4	29
32	Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2. Viruses, 2021, 13, 2183.	3.3	8
33	Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike. MBio, 2021, 12, e0297521.	4.1	24
34	HER2-mediated enhancement of Ebola virus entry. PLoS Pathogens, 2020, 16, e1008900.	4.7	17
35	Formulation and production of a blood-free and chemically defined virus production media for VERO cells. Biotechnology and Bioengineering, 2020, 117, 3277-3285.	3.3	3
36	Revealing fine-scale spatiotemporal differences in SARS-CoV-2 introduction and spread. Nature Communications, 2020, 11, 5558.	12.8	39

#	ARTICLE	IF	CITATIONS
37	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. <i>Science</i> , 2020, 370, 1464-1468.	12.6	808
38	Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 856.	3.7	2
39	Transmission of SARS-CoV-2 in Domestic Cats. <i>New England Journal of Medicine</i> , 2020, 383, 592-594.	27.0	430
40	Identification of interferon-stimulated genes that attenuate Ebola virus infection. <i>Nature Communications</i> , 2020, 11, 2953.	12.8	37
41	Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 16587-16595.	7.1	912
42	Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007654.	3.0	12
43	Isolation of Highly Pathogenic H5N1 Influenza Viruses in 2009â€“2013 in Vietnam. <i>Frontiers in Microbiology</i> , 2019, 10, 1411.	3.5	5
44	Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection. <i>Cell</i> , 2019, 177, 1566-1582.e17.	28.9	153
45	Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	15
46	Plasma lipidome reveals critical illness and recovery from human Ebola virus disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3919-3928.	7.1	62
47	Mutations in the PA Protein of Avian H5N1 Influenza Viruses Affect Polymerase Activity and Mouse Virulence. <i>Journal of Virology</i> , 2018, 92, .	3.4	36
48	The Induction of IL-1 β Secretion Through the NLRP3 Inflammasome During Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2018, 218, S504-S507.	4.0	22
49	A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. <i>Cell Host and Microbe</i> , 2018, 24, 221-233.e5.	11.0	182
50	MPLEX: a method for simultaneous pathogen inactivation and extraction of samples for multi-omics profiling. <i>Analyst</i> , 2017, 142, 442-448.	3.5	43
51	The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses. <i>Journal of Virology</i> , 2016, 90, 3086-3092.	3.4	133
52	Ebola Virus Stability Under Hospital and Environmental Conditions. <i>Journal of Infectious Diseases</i> , 2016, 214, S142-S144.	4.0	13
53	Crystal Structure of Marburg Virus VP40 Reveals a Broad, Basic Patch for Matrix Assembly and a Requirement of the N-Terminal Domain for Immunosuppression. <i>Journal of Virology</i> , 2016, 90, 1839-1848.	3.4	33
54	Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection. <i>Journal of Infectious Diseases</i> , 2015, 212, S329-S335.	4.0	18

#	ARTICLE	IF	CITATIONS
55	Identification of mammalian-adapting mutations in the polymerase complex of an avian H5N1 influenza virus. <i>Nature Communications</i> , 2015, 6, 7491.	12.8	91
56	An Ebola whole-virus vaccine is protective in nonhuman primates. <i>Science</i> , 2015, 348, 439-442.	12.6	81
57	Pseudoparticle Neutralization Assay for Detecting Ebola- Neutralizing Antibodies in Biosafety Level 2 Settings. <i>Clinical Chemistry</i> , 2015, 61, 885-886.	3.2	5
58	Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection. <i>Journal of Virology</i> , 2015, 89, 10399-10406.	3.4	34
59	Ebola Conquers West Africa – More to Come?. <i>EBioMedicine</i> , 2014, 1, 2-3.	6.1	1
60	Novel residues in avian influenza virus PB2 protein affect virulence in mammalian hosts. <i>Nature Communications</i> , 2014, 5, 5021.	12.8	73
61	Structural Rearrangement of Ebola Virus VP40 Begets Multiple Functions in the Virus Life Cycle. <i>Cell</i> , 2013, 154, 763-774.	28.9	201
62	DNA Topoisomerase 1 Facilitates the Transcription and Replication of the Ebola Virus Genome. <i>Journal of Virology</i> , 2013, 87, 8862-8869.	3.4	29
63	The spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cells. <i>Scientific Reports</i> , 2013, 3, 1206.	3.3	123
64	The Cytoprotective Enzyme Heme Oxygenase-1 Suppresses Ebola Virus Replication. <i>Journal of Virology</i> , 2013, 87, 13795-13802.	3.4	81
65	Structure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus. <i>Journal of Virology</i> , 2012, 86, 2809-2816.	3.4	46
66	A shared structural solution for neutralizing ebolaviruses. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 1424-1427.	8.2	113
67	The Ebolavirus VP24 Protein Blocks Phosphorylation of p38 Mitogen-Activated Protein Kinase. <i>Journal of Infectious Diseases</i> , 2011, 204, S953-S956.	4.0	40
68	Ebolavirus Is Internalized into Host Cells via Macropinocytosis in a Viral Glycoprotein-Dependent Manner. <i>PLoS Pathogens</i> , 2010, 6, e1001121.	4.7	366
69	Replication-Deficient Ebolavirus as a Vaccine Candidate. <i>Journal of Virology</i> , 2009, 83, 3810-3815.	3.4	73
70	Generation of biologically contained Ebola viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 1129-1133.	7.1	113
71	Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. <i>Nature</i> , 2007, 445, 319-323.	27.8	892
72	Characterization of a Human H5N1 Influenza A Virus Isolated in 2003. <i>Journal of Virology</i> , 2005, 79, 9926-9932.	3.4	90

#	ARTICLE	IF	CITATIONS
73	Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature, 2004, 431, 703-707.	27.8	434
74	Genetic incompatibility among influenza A viruses. International Congress Series, 2001, 1219, 1019-1021.	0.2	0
75	Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses. Science, 2001, 293, 1840-1842.	12.6	1,218
76	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	27.8	101